PATENT CLAIM ANALYSIS

Application Number: 16149522
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-01
Patent Classification: ["514", "210180"]

Abstract:
The problem to be solved by the present invention is to provide an anticancer agent for treating tumors resistant to other antitumor agents that inhibit FGFR, and a method for treating such tumors. The present invention provides an antitumor agent for administration to a tumor patient resistant to an FGFR inhibitor, the antitumor agent comprising a 3,5-disubstituted benzene alkynyl compound represented by Formula (I) below or a salt thereof. The present invention also provides a therapeutic method using the anticancer agent.

Claim (Index 32):
The use according to  claim 25 , wherein the 3,5-disubstituted benzene alkynyl compound or a salt thereof is (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 97.0
- Lexical Diversity: 1.69231
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14905047', '13859569', '14344935', '15575448', '13617035']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7621836801380926
- 35 USC 102 Novelty (BERT): 0.6021587548091453
- Combined Prediction Score: 0.7461811876051979
- Mean Citation Score: 361.98346
- Max Citation Score: 551.84607
- Similarity Product: 431.6282622659755

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test